Medical management of Benign Prostate Hyperplasia: New insights

Abstract

Benign prostatic hyperplasia (BPH) is a very common disease of elderly men. The development of effective medical treatment of BPH has resulted in decreased need for invasive surgical interventions lately. In the initial stage, watchful waiting and lifestyle modification may be sufficient. There are a few treatment options which are available for treatment of BPH. Various strongly designed placebo controlled clinical trials like the Veterans Affair study( VA) study and the PREDICT study have shown the value of treating BPH in general population with monotherapy using an alpha blocker. But there is some evidence of superiority of combination therapy with an alpha blocker and 5 alpha reductive inhibitors in patients of BPH with large prostate sizes. Some newer drugs like NX-1207 and GNRH agonists, and some new techniques like Intraprostatic toxin type-A have also been studied for their usefulness in BPH. All of these new treatment options have shown promise in initial research.